APA (7th ed.) Citation

MS, K., M, S., J, O., AA, A., S, M., K, Q., . . . P, R. (2022). Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer's disease therapeutic. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 42(5), 788. https://doi.org/10.1177/0271678X211035625

Chicago Style (17th ed.) Citation

MS, Kang, et al. "Preclinical in Vivo Longitudinal Assessment of KG207-M as a Disease-modifying Alzheimer's Disease Therapeutic." Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism 42, no. 5 (2022): 788. https://doi.org/10.1177/0271678X211035625.

MLA (9th ed.) Citation

MS, Kang, et al. "Preclinical in Vivo Longitudinal Assessment of KG207-M as a Disease-modifying Alzheimer's Disease Therapeutic." Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism, vol. 42, no. 5, 2022, p. 788, https://doi.org/10.1177/0271678X211035625.